Figure 1

Intratumoral injection with Ad5IL-12 vector and 1 week treatment with RU486 synergistically attenuates the growth of human PC3 tumors. Xenograft tumors established SC in NOD.scid mice were treated at week 3 by IT injection with 50 μl of PBS containing 5 × 10⁸ pfu of Ad5IL-12 (filled squares) or control DL70-3 vector (empty squares) or PBS alone (empty circles). In addition, another set of mice were treated with Ad5IL-12 IT injection and given daily IP injections of RU486 for 7 days (black triangles). Data points are expressed as the mean ± SE. n = 8 for each data point. * indicates statistical significance of P < 0.05 for Ad5IL-12 + RU486 treatments alone compared to controls. Tumor volumes measured at 8 weeks were 3394 ± 87 mm³ for PBS, 3163 ± 87 mm³ for DL70-3, 1989 ± 307 for RU486, 668 ± 87 mm³ for Ad5IL-12 and 298 ± 120 mm³ for Ad5IL-12 + RU486 treatment groups.